Centene
Local health insurance and care services
Account Executive - Specialty Pharmacy
More locations: North Carolina, USA
Candidates must live within an hour of Raleigh or Richmond. Travel is approximately 30%, including overnight travel.
About the job
- A bachelor's degree in Business Administration, a related field, or equivalent experience.
- Prior sales experience.
- A current state driver's license.
- Ability to travel 30%, including overnight travel.
- Represent the company to prospective and existing clients, monitor client satisfaction, and recommend changes to enhance satisfaction.
- Drive specialty pharmacy growth by building provider relationships, managing referral pipelines, ensuring timely patient access to therapies, and collaborating with clinical, access, and manufacturer partners.
- Serve as the contact for client issues and inquiries and collaborate with departments to resolve them.
- Develop and maintain relationships with clients at various levels and use the current network to identify additional accounts.
- Negotiate account renewals, contracts, and intake referral processes.
- Attend patient care conferences and professional in-services to support new products and strategies.
- Maximize territory performance by prioritizing key accounts, managing referral flow, and executing daily schedules through customer relationship management planning.
- Strengthen provider relationships through in-person and virtual engagement, deliver education on specialty therapies, and resolve access barriers.
- Coordinate with hubs, case managers, and payers to expedite prior authorizations, documentation, and patient onboarding.
- Collaborate with pharmacists, access teams, and manufacturer partners to align strategies and deliver cohesive support.
- Deliver education and training for provider offices, staff, and stakeholders, and stay current on therapeutic and payer landscape updates.
- Use data and reporting to track referral trends, identify territory gaps, and provide actionable insights to leadership.
- Drive growth initiatives by targeting new prescribers, infusion centers, and community opportunities that expand the specialty pharmacy footprint.
- Perform other duties as assigned and comply with applicable policies and standards.
- Clinical patient support experience in a physician's office, hospital, or pharmacy setting.
- Knowledge of third-party reimbursement.
About the company
Centene provides health insurance and related health services to underinsured and uninsured individuals, serving primarily through the Health Insurance Marketplace and a network of local brands and teams across the United States. It collects premiums from members and delivers access to medical, dental, vision, behavioral health, and pharmacy benefits, aiming to offer cost-effective care. The company differentiates itself with a localized, community-focused operating model that tailors offerings to each community while leveraging a wide range of services and scale to manage costs. Its goal is to improve health outcomes and overall well-being for its members while maintaining responsible governance and sustainability efforts on environmental and social fronts.
Company Size
10,001+
Company Stage
IPO
Headquarters
St. Louis, Missouri
Founded
1984
Get referred to Centene
See people who can refer or advise you
Simplify's Take
What believers are saying
- July 28, 2026 adjusted EPS reached $2.51, crushing consensus $1.09.
- Centene raised 2026 adjusted EPS guidance above $4.80 and revenue to $193.5-$197.5 billion.
- Bradley Bolivar’s August 31 CIO appointment and Chris Neczypor’s CFO transition strengthen execution.
What critics are saying
- CMS imposed a May 1, 2026 Medicare penalty after 2022 overcharging findings.
- The July 9, 2025 securities suit and 2026 derivative cases keep executive distraction alive.
- Marketplace membership fell to 3.5 million, while Medicaid attrition hit 9% guidance by year-end.
What makes Centene unique
- Centene dominates Medicaid and Marketplace nationally through local brands and state-specific operations.
- Its July 28, 2026 results showed $53.6 billion revenue and raised 2026 EPS guidance.
- August 25, 2026 Evolent expansion deepens Centene’s oncology cost-management capabilities in Medicare Advantage.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Hybrid Work Options
Flexible Work Hours
Company News
Centene has drawn renewed attention for its earnings outlook, attractive valuation, and exposure to growing ICHRA-driven individual coverage through its Ambetter Health Solutions business. The health insurer has delivered strong returns, with shares up 9.96% over 90 days and 60.60% year to date. Analysts estimate Centene's fair value at $71.67 versus its last close of $67.10, suggesting the stock is roughly 6% undervalued. The valuation assumes 4.5% annual revenue growth over three years and profit margins improving from -2.8% to 1.5% during that period. Bulls cite the company's value score, earnings momentum, and ICHRA exposure as drivers for further gains. Bears caution that the recent share price surge may have outpaced fundamental improvements. Key risks include potential Medicaid rate disappointments and faster-than-expected increases in medical costs, particularly for speciality drugs.
Centene (NYSE:CNC) hits new 1-year high - here's why. September 14, 2026 Key points. * Centene shares hit a new 52-week high of $69.58, trading up 4.6% from the prior close, with a market capitalization of approximately $34.33 billion. * The company significantly exceeded quarterly expectations, reporting EPS of $2.51 versus the $1.09 consensus and revenue of $53.58 billion versus $47.64 billion expected. Revenue increased 9.9% year over year. * Analyst sentiment is mixed but improving: Argus and Zacks upgraded the stock, while Truist raised its price target to $78; the overall consensus remains "Hold" with a $70.05 target price. * Five stocks we like better than Centene. Shares of Centene Corporation (NYSE:CNC - Get Free Report) hit a new 52-week high during trading on Monday. The stock traded as high as $69.58 and last traded at $69.5220, with a volume of 2269238 shares trading hands. The stock had previously closed at $66.42. Analyst upgrades and downgrades. Several analysts recently issued reports on the stock. Morgan Stanley set a $66.00 price objective on shares of Centene in a report on Wednesday, July 29th. Argus raised shares of Centene from a "hold" rating to a "buy" rating and set a $80.00 target price for the company in a research report on Tuesday, August 11th. Truist Financial raised their price objective on shares of Centene from $71.00 to $78.00 and gave the stock a "buy" rating in a research note on Tuesday, July 14th. Zacks Research upgraded Centene from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, July 29th. Finally, Weiss Ratings reiterated a "sell (d)" rating on shares of Centene in a research report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $70.05. Centene trading up 4.6%. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.15 and a quick ratio of 1.15. The business's 50 day simple moving average is $65.45 and its 200 day simple moving average is $55.07. The stock has a market cap of $34.33 billion, a P/E ratio of -6.65, a PEG ratio of 0.42 and a beta of 1.10. Centene (NYSE:CNC - Get Free Report) last issued its earnings results on Monday, July 27th. The company reported $2.51 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.09 by $1.42. The business had revenue of $53.58 billion during the quarter, compared to analysts' expectations of $47.64 billion. Centene had a positive return on equity of 12.12% and a negative net margin of 2.51%.Centene's quarterly revenue was up 9.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.16) EPS. On average, analysts expect that Centene Corporation will post 4.89 earnings per share for the current fiscal year. Insider activity at Centene. In other news, General Counsel Christopher Koster sold 56,500 shares of the business's stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $66.90, for a total value of $3,779,850.00. Following the sale, the general counsel owned 248,854 shares in the company, valued at approximately $16,648,332.60. The trade was a 18.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.37% of the company's stock. Institutional trading of Centene. Large investors have recently added to or reduced their stakes in the company. Sequoia Financial Advisors LLC boosted its holdings in shares of Centene by 11.1% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 37,577 shares of the company's stock worth $2,412,000 after acquiring an additional 3,760 shares in the last quarter. National Pension Service increased its holdings in Centene by 353.0% during the 2nd quarter. National Pension Service now owns 939,674 shares of the company's stock valued at $60,318,000 after purchasing an additional 732,259 shares in the last quarter. Cidel Asset Management Inc. raised its position in Centene by 9.1% in the 2nd quarter. Cidel Asset Management Inc. now owns 27,321 shares of the company's stock valued at $1,754,000 after purchasing an additional 2,271 shares during the last quarter. NorthRock Partners LLC bought a new stake in shares of Centene during the second quarter worth $209,000. Finally, Arizona State Retirement System increased its stake in shares of Centene by 5.6% in the second quarter. Arizona State Retirement System now owns 140,997 shares of the company's stock valued at $9,051,000 after buying an additional 7,471 shares in the last quarter. 93.63% of the stock is owned by institutional investors. About Centene. Centene Corporation NYSE: CNC is a managed-care company that provides health insurance and related healthcare services, primarily through government-sponsored programs. Its offerings include Medicaid, Medicare Advantage and Medicare Prescription Drug plans, coverage for individuals and families through the health insurance marketplace, and health services for military families and veterans. The company markets several healthcare brands, including Ambetter, which provides marketplace plans, and Wellcare, which offers Medicare products. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Centene, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centene wasn't on the list. While Centene currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Enter your email address and we'll send you MarketBeat's list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Continue following MarketBeat
The health insurance industry may have recovered from high medical costs, with analysts predicting strong growth through 2030. Morningstar forecasts 16% annual earnings per share growth for major insurers, above the industry's typical low-double-digit target. Health insurers are improving profitability by raising rates to cover increased medical utilisation. UnitedHealth Group reported over $5 billion in second-quarter net income, with its medical care ratio falling to 86.7% from 89.4% year-over-year. The outlook also improved for pharmacy benefit management operations at companies like UnitedHealth, CVS Health, and Cigna. Despite increased regulatory scrutiny, the "big three" PBMs maintain strong competitive positions. Third-quarter earnings reports next month should provide further clarity on the industry's financial health.
Centene (CNC) hands its turnaround playbook to A new tech Chief. Published on September 2, 2026 at 3:23 am by maham fatima in hedge funds, news. On August 31, Centene Corporation (NYSE:CNC) named Bradley Bolivar its new Chief Information Officer, taking over from Brian LeClaire, who plans to retire by the end of October 2026. Bolivar arrives with nearly three decades of technology leadership, most recently as CIO of Fannie Mae, where his portfolio spanned application development, infrastructure, cybersecurity, data and artificial intelligence. CEO Sarah London framed the move as central to how the health insurer plans to operate, calling data, technology and AI "strategic capabilities" rather than back office support. A modernizer arrives with momentum behind him. Bolivar's résumé reads like a checklist for what a sprawling health insurer needs right now. At Fannie Mae, he pushed enterprise modernization, tightened technology resilience and governance, and expanded the use of AI and automation to improve operations. His background also spans financial services, media and consulting, including a senior leadership stint at Warner Bros. Entertainment, giving him experience outside the narrow confines of healthcare IT. That matters because he is not walking into a company still searching for financial footing. In its July 28 earnings report, Centene posted second-quarter GAAP diluted earnings per share of $2.19 and adjusted diluted earnings per share of $2.51, and it raised its full-year adjusted EPS guidance floor to above $4.80. The company's consolidated health benefits ratio improved to 89.6% from 93.0% a year earlier, and its Commercial segment ratio fell to 79.2%, a notable year-over-year decline. London's comment that Centene is "entering a new era" carries more weight against that backdrop, and Bolivar's own remark about reimagining technology to serve underserved populations lands as more than a talking point when the balance sheet backs it up. LeClaire's planned, orderly exit at the end of October also gives the handoff room to breathe rather than forcing a scramble. The membership math still weighs. The profitability gains sit next to a shrinking customer base. Total at-risk membership fell from 28.0 million in June 2025 to 25.9 million in June 2026, and the damage was not spread evenly. Marketplace membership collapsed from 5.86 million to 3.49 million over that stretch, while Medicaid slipped from 12.82 million to 12.11 million. Medicare Prescription Drug Plan enrollment grew, from 7.85 million to 8.80 million, but the July 28 filing notes that business "operates at a meaningfully lower SG&A expense ratio" than the company overall, a different kind of growth than replacing lost Marketplace lives. Medicaid's health benefits ratio came in at 93.9%, which Centene called "in-line with expectations" but which still reflects ongoing cost pressure in its largest segment. Roughly $0.50 of the guidance increase came from non-recurring items in Medicare and Commercial, a detail that tempers how much of the improvement is durable. Bolivar now inherits the job of modernizing technology across three insurance lines moving in different directions, one shrinking, one growing but thinner-margined, and one still working through elevated medical costs, all while a departing CIO's institutional knowledge walks out the door in October. Market sentiment. 72 hedge funds held Centene shares last quarter, unchanged from the quarter before, pointing to steady rather than accelerating institutional interest. Short sellers account for just 3.08% of the float, a level that suggests little organized skepticism toward the stock. Centene trades at a forward price-to-earnings ratio of 13.12 as of September 1, a modest multiple for a company that just raised its adjusted EPS guidance floor above $4.80. Flat fund positioning, light short interest, and a low multiple together suggest the market has not fully priced in Centene's recent margin improvement, or is still waiting to see if it holds. Conclusion. Centene enters this leadership change from sturdier financial ground than it had a year ago, but the enrollment losses in Marketplace and Medicaid remain unresolved. Bolivar takes charge of technology strategy at a moment when the company is leaning on AI and data to manage costs across three very different books of business. LeClaire's planned departure at the end of October gives him a running start rather than a rushed transition. Whether that technology push shows up in enrollment trends or medical cost ratios will take more than one earnings cycle to judge.
Centene Corporation has appointed Bradley Bolivar as chief information officer, effective 31 August. Bolivar brings nearly three decades of technology leadership experience from roles at Fannie Mae, where he most recently served as CIO, and Warner Bros. Entertainment. At Fannie Mae, Bolivar led enterprise technology strategy across application development, infrastructure, cybersecurity, data, and artificial intelligence. He accelerated modernisation efforts and expanded the use of AI and automation to improve operational performance. Chief executive officer Sarah London said Bolivar's ability to solve complex technology challenges will help Centene deliver improved health experiences for underserved populations. Bolivar succeeds Brian LeClaire, who will retire by end of October 2026 as planned. Centene is a Fortune 500 healthcare company serving government-sponsored and commercial healthcare programmes.